Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30620315 | 1.00 | LPL (0.47) | LPLLIPGCYP2A6SNCACA1 | |
| SCHEMBL20984006 | 0.89 | LIPG (0.60) | LPLLIPGSNCACA2CA12 | |
| SCHEMBL14727556 | 0.88 | LPL (0.46) | LPLLIPGSNCACA1CA2 | |
| SCHEMBL20427816 | 0.87 | LPL (0.38) | LPLLIPGCYP2A6SNCACA2 | |
| SCHEMBL20180339 | 0.84 | LIPG (0.50) | LPLLIPGSNCACA2CA12 | |
| SCHEMBL31500638 | 0.83 | LPL (0.43) | LPLLIPGSNCACA1CA2 | |
| SCHEMBL31500569 | 0.81 | LPL (0.40) | LPLLIPGSNCACA1CA2 | |
| SCHEMBL29644319 | 0.79 | LPL (0.62) | LPLLIPGSNCACA1CA2 | |
| SCHEMBL1293460 | 0.79 | LPL (0.62) | LPLLIPGSNCACA1CA2 | |
| SCHEMBL27292385 | 0.78 | CSF1R (0.41) | LPLLIPGSNCACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735429-A1 | TRIAZINE DERIVATIVES AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| WO-2025106014-A1 | COMPOUNDS AND METHODS FOR PKMYT1 INHIBITION | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025087274-A1 | AZABICYCLO DERIVATIVE AND PREPARATION METHOD THEREFOR, AND USE | 浙江海正药业股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| EP-4540255-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| WO-2025003288-A1 | TRIAZINE DERIVATIVES AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-02 | — | — | WO | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| EP-4419532-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| WO-2006103273-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
| US-20060183736-A1 | Selective estrogen receptor modulators containing a phenylsulfonyl group | ELILILLY AND COMPANY | 2006-08-17 | — | — | US | disclosed |
| EP-1506190-B1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | HOFFMANN LA ROCHE (CH) | 2006-06-14 | — | — | EP | disclosed |
| US-7005432-B2 | Substituted imidazol-pyridazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-02-28 | — | — | US | disclosed |
| EP-1530470-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | ELI LILLY AND COMPANY (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| WO-2004009086-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | ELI LILLY AND COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | LPL 230/4885LIPG 232/4885CYP2A6 421/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | LPL 230/4885LIPG 232/4885CYP2A6 421/4885 |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | LPL 4579/4885LIPG 3220/4885CYP2A6 3411/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | LPL 230/4885LIPG 232/4885CYP2A6 421/4885 |
| US-20060183736-A1 | Selective estrogen receptor modulators containing a phenylsulfonyl group | GPER1, ESR2, ESR1 | LPL 4114/4885LIPG 1947/4885CYP2A6 329/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | LPL 4579/4885LIPG 3220/4885CYP2A6 3411/4885 |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | GRIN2B, GRIN2A, GRIN2C | LPL 4626/4885LIPG 4808/4885CYP2A6 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.